New therapeutic target for Alzheimer's could lead to drugs without side effects

But new research from Rockefeller University, published in the Feb. 26 online edition of Proceedings of the National Academy of Sciences, has identified a therapeutic target, called casein kinase 1, that may be the key to halting the course of the disease. The findings, based on studies in mammalian cells, show that chemicals that block casein kinase 1 don't interfere with a closely connected essential pathway.

Alzheimer's disease is caused by a build-up of a small protein called beta-amyloid, which is formed when a larger protein is broken into pieces. But the enzyme that produces beta-amyloid is also responsible for cleavage of another protein called Notch. The problem with current drugs is that they block these enzymes to stop production of beta-amyloid, and in doing so they also block the cleavage of Notch — which plays an important role in the development of healthy brain cells.

The new research, based on studies by lead author Marc Flajolet and from the Nobel Prize winning laboratory of Paul Greengard, director of the Fisher Center for Alzheimer's Disease Research at Rockefeller, has identified another protein, casein kinase 1, that controls the regulation of these enzymes. When the researchers block casein kinase 1, production of beta-amyloid proteins goes down, but Notch signaling is not affected.

“Studies of brain tissue from Alzheimer's patients have shown an increase in casein kinase 1 expression,” says Greengard, Vincent Astor Professor and head of the Laboratory of Molecular and Cellular Neuroscience. “We found that the key enzymes involved in beta-amyloid production – called BACE and gamma-secretase – were targets of casein kinase 1, so we investigated what role it might be playing.”

The scientists modified mouse cells to generate a form of casein kinase 1 that was always active, and found that these cells produced more beta-amyloid protein than normal. Then, using three different types of chemicals, they blocked the protein from functioning. When they did this, they were able to reverse the production of beta-amyloid protein, without affecting the signaling of Notch proteins.

The studies suggest that an Alzheimer's therapy based on these chemicals could reduce or halt beta-amyloid build-up without causing side effects. “Numerous efforts have been directed at the development of drugs that inhibit gamma-secretase,” says Greengard, “but there have been significant side effects in animal studies. Our hope is that this research might lead to drugs that don't have those problems.”